These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24035782)
21. Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoeitic stem cell transplantation: A single institution experience. Ali S; Wall DA; Ali M; Chiang KY; Naqvi A; Weitzman S; Gassas A; Gibson P; Brager R; Fernandez CV; Crooks B; Schechter T; Krueger J Pediatr Blood Cancer; 2020 Sep; 67(9):e28477. PubMed ID: 33740322 [TBL] [Abstract][Full Text] [Related]
22. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. Khandelwal P; Bleesing JJ; Davies SM; Marsh RA Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157 [TBL] [Abstract][Full Text] [Related]
23. Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. Wustrau K; Greil J; Sykora KW; Albert MH; Burkhardt B; Lang P; Meisel R; Wössmann W; Beier R; Schulz A; Bader P; Chada M; Kühl JS; Schlegel PG; Speckmann C; Gruhn B; Seidel M; Wawer A; Ozga AK; Janka G; Ehl S; Müller I; Lehmberg K Pediatr Blood Cancer; 2020 Sep; 67(9):e28523. PubMed ID: 32618429 [TBL] [Abstract][Full Text] [Related]
24. Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning. Chellapandian D; Krueger J; Schechter T; Gassas A; Weitzman S; Naqvi A; Ali M Pediatr Blood Cancer; 2016 Feb; 63(2):355-7. PubMed ID: 26398727 [TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M; Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820 [TBL] [Abstract][Full Text] [Related]
26. A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants. Jardine L; Publicover A; Bigley V; Hale G; Pearce K; Dickinson A; Jackson G; Collin M Br J Haematol; 2015 Mar; 168(6):874-81. PubMed ID: 25640315 [TBL] [Abstract][Full Text] [Related]
27. The Role of Hematopoietic Stem Cell Transplantation in Treatment of Hemophagocytic Lymphohistiocytosis. Nikiforow S Hematol Oncol Clin North Am; 2015 Oct; 29(5):943-59. PubMed ID: 26461153 [TBL] [Abstract][Full Text] [Related]
28. Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis. Worth AJ; Nikolajeva O; Chiesa R; Rao K; Veys P; Amrolia PJ Blood; 2013 Jun; 121(24):4966-8. PubMed ID: 23766462 [No Abstract] [Full Text] [Related]
29. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
31. A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. Parikh SH; Mendizabal A; Benjamin CL; Komanduri KV; Antony J; Petrovic A; Hale G; Driscoll TA; Martin PL; Page KM; Flickinger K; Moffet J; Niedzwiecki D; Kurtzberg J; Szabolcs P Biol Blood Marrow Transplant; 2014 Mar; 20(3):326-36. PubMed ID: 24296492 [TBL] [Abstract][Full Text] [Related]
32. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Cooper N; Rao K; Gilmour K; Hadad L; Adams S; Cale C; Davies G; Webb D; Veys P; Amrolia P Blood; 2006 Feb; 107(3):1233-6. PubMed ID: 16219800 [TBL] [Abstract][Full Text] [Related]
33. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Gooptu M; Kim HT; Jacobsen E; Fisher DC; LaCasce A; Ho VT; Cutler CS; Koreth J; Soiffer RJ; Antin JH; Berliner N; Nikiforow S Blood Adv; 2023 Jun; 7(11):2309-2316. PubMed ID: 35439287 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Patel K; Parmar S; Shah S; Shore T; Gergis U; Mayer S; van Besien K Biol Blood Marrow Transplant; 2016 Mar; 22(3):456-61. PubMed ID: 26524732 [TBL] [Abstract][Full Text] [Related]
35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH. Hege K; Quigg T; Delgado D Pediatr Blood Cancer; 2016 Feb; 63(2):361-3. PubMed ID: 26488531 [TBL] [Abstract][Full Text] [Related]
39. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. van Besien K; Kunavakkam R; Rondon G; De Lima M; Artz A; Oran B; Giralt S Biol Blood Marrow Transplant; 2009 May; 15(5):610-7. PubMed ID: 19361753 [TBL] [Abstract][Full Text] [Related]
40. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. Nikolousis E; Robinson S; Nagra S; Brookes C; Kinsella F; Tauro S; Jeffries S; Griffiths M; Mahendra P; Cook M; Paneesha S; Lovell R; Kishore B; Chaganti S; Malladi R; Raghavan M; Moss P; Milligan D; Craddock C Leuk Res; 2013 May; 37(5):561-5. PubMed ID: 23395505 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]